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RNA molecules have emerged as promising therapeutics. Like
all other drugs, the safety profile and immune response are
important criteria for drug evaluation. However, the litera-
ture on RNA immunogenicity has been controversial. Here,
we used the approach of RNA nanotechnology to demon-
strate that the immune response of RNA nanoparticles is
size, shape, and sequence dependent. RNA triangle, square,
pentagon, and tetrahedron with same shape but different
sizes, or same size but different shapes were used as models
to investigate the immune response. The levels of pro-inflam-
matory cytokines induced by these RNA nanoarchitectures
were assessed in macrophage-like cells and animals. It was
found that RNA polygons without extension at the vertexes
were immune inert. However, when single-stranded RNA
with a specific sequence was extended from the vertexes of
RNA polygons, strong immune responses were detected.
These immunostimulations are sequence specific, because
some other extended sequences induced little or no immune
response. Additionally, larger-size RNA square induced
stronger cytokine secretion. 3D RNA tetrahedron showed
stronger immunostimulation than planar RNA triangle.
These results suggest that the immunogenicity of RNA nano-
particles is tunable to produce either a minimal immune
response that can serve as safe therapeutic vectors, or a
strong immune response for cancer immunotherapy or
vaccine adjuvants.
INTRODUCTION
When the first human genome was completely sequenced a decade
ago, it was found that only 1.5% of the human genome codes for pro-
tein.1 A large portion of the remaining 98.5% was proposed to be
“Junk DNA.”2 However, more and more evidence revealed that a sub-
stantial part of the so-called Junk DNA encodes small non-coding
RNA.3,4 Recently, many long non-coding RNAs were identified
with the advancement of technology, making it possible to charac-
terize long non-coding RNA molecules.5 It has been predicted that
the third milestone in drug development will be RNA drugs, either
RNA itself as drugs or chemicals/ligands that target RNA, following
the first milestone of chemical drugs and the second milestone of pro-
tein drugs including antibodies, enzymes, hormones, or chemicals/li-
gands that target proteins.6
Many small RNA oligos and moieties, such as short interfering RNA
(siRNA),7,8 microRNA (miRNA),9,10 ribozymes,11,12 aptamers,13
and riboswitches,14 have been reported to be potential powerful
therapeutics. Meanwhile, a variety of RNA species or analogs have
also been reported to be immunogenic. These include viral single-
stranded RNA (ssRNA),15,16 double-stranded RNA (dsRNA),17,18
specific mRNA,19,20 specific siRNA,21–23 immune checkpoint RNA
aptamers,24–26 and inosine incorporated synthetic RNA.27,28 Previ-
ous studies have identified the immunological targets for these spe-
cial RNA molecules, including cell surface or endosome Toll-like
receptors (TLRs; TLR-3, -7, -8, and -9)15–18,29 and cytosolic sensors
(protein kinase R [PKR], RIG-I, and MDA-5).30–33 Recognition of
these specific RNA sequences (SEQs) or structures by their corre-
sponding immune receptors will trigger a series of immune events
that are part of the host’s natural defense, including cytokine secre-
tion, immune cell proliferation and survival, or activation of adap-
tive immunity.
The RNA nanotechnology concept was proposed in 1998 by
showing that RNA dimers, trimers, tetramers, and hexamers can
self-assemble from reengineered RNA monomers by a bottom-up
assembly approach.34 Consequently, the field of RNA nanotech-
nology has emerged rapidly.35–45 This field is the study of RNA ar-
chitectures in nanoscale with their major frame composed of RNA.
In these nanoarchitectures, the scaffolds, targeting ligands, thera-
peutics, or regulators are mainly made up of RNA. The applications
of RNA nanotechnology in cancer therapy have been extensively
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investigated.35,36,46–53 RNA nanoparticles display distinct attributes
including controllable size, shape, and stoichiometry, favorable ther-
modynamic stability in vitro and in vivo, specific targeting for
diseased cells, and low accumulation in the liver and other vital
organs.38–45,54–57 Many RNA nanoparticles have been reported to
be safe because they are negatively charged, and thus have a lower
intention to bind to or enter normal cells that contain negatively
charged cell membrane. Consequently, RNA nanoparticles have lit-
tle impairment effect on normal cells or vital tissues46–49,53,58 and do
not induce cytokine or interferon.59,60 The chemical properties of
RNA nanoparticles are similar to siRNA, miRNA, ribozymes, ap-
tamers, riboswitches, or other immunogenic RNA in that they are
all composed of ribonucleotides. The main difference is that RNA
nanoparticles are larger in size and are constructed by bottom-up
self-assembly of multiple RNA oligos. This raises an interesting
question of whether the size or shape of RNA plays a role in trig-
gering potential immune response and toxicity, because RNA nano-
particles are similar in size to viruses. Additionally, it was reported
that immunostimulatory nucleic acid molecules have been incorpo-
rated into phi29-based RNA polygons to enhance immunomodula-
tion in vivo, while RNA polygons themselves display little to no
immunoactivity.59 Other studies reported that the immunological
properties of a hybrid RNA/DNA cube can be conditionally
controlled by tuning the ratio between RNA/DNA strands.61,62
These raise another question whether the RNA SEQ plays a role
in triggering immune response and toxicity.
Toxicity, side effects, and immunogenicity are some of the most
important criteria in drug evaluation, aside from drug efficacy and
shelf life. A thorough investigation of the immune-compatibility of
RNA nanoparticles is important for their translation to the
clinic.63–65 To help explore the basic mechanism of the immunoge-
nicity of RNA nanoparticles, here we use RNA polygons and tetrahe-
dron (Th) that have the same size but different shapes or the same
shape with different sizes, and variable SEQ extensions, as model
systems. It was found that their immunomodulatory property is
dependent on size, shape, and sequence. Our results suggest that
RNA nanoparticles can be manually designed using their program-
mable property to exhibit no, low, or high immunogenicity, allowing
for the development of potential RNA-based immunomodulators for
cancer immunotherapy or as vaccine adjuvants.
RESULTS
Design, Self-Assembly, and Physicochemical Characterization
of RNA Nanoparticles with Extended Special SEQ
Different RNA SEQs were incorporated into RNA square (SQR) by
direct extension of the four external sticky ends (Figure 1A). To
examine the assembly, we evaluated the stepwise annealing of
SQRs containing increasing copies of extended SEQs by gel electro-
phoresis. The observed homogeneous bands (Figure 1B) and size
assessment by dynamic light scattering (DLS) (Figure 1C) confirm
the expected formation of the designed nanoparticles and high as-
sembly yield. By altering the length of each side of the SQR, smaller
and larger SQR-SEQ nanoparticles were constructed using the same
approach (Figure S1). The average hydrodynamic diameter (Dh)
distribution was determined to be 7.10 ± 0.93, 12.31 ± 0.95, and
21.15 ± 2.20 nm for small, medium, and large SQR-SEQ nanopar-
ticles, respectively (Figure 1C). By changing the number of external
Figure 1. Assembly and Size Characterization of 2’F RNA Nanoparticles
(A) Assembly of 20F SQR-SEQ with 3D modeled structures are shown. (B) Stepwise assembly of 20F SQR-SEQ with different numbers of modules, evaluated by 3% agarose
gel (ladder: 100 bp DNA). (C and D) Size distribution of small, medium, and large RNA nanoparticles measured by DLS (n = 3). D, dimer; M, monomer; T, trimer; Tetra,
tetramer.
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RNA strands of the medium SQR-SEQ nanoparticle, a triangle-SEQ
(TRI-SEQ) and a pentagon-SEQ (PENTA-SEQ) were constructed
with 10.72 ± 1.87 and 13.85 ± 1.45 nm of average Dh (Figure 1D).
Next, a serum degradation assay was performed to evaluate the
enzymatic stability of 20-fluorine (20F)-modified SQR-SEQ. Four
SQR-SEQ nanoparticles with different compositions (20F SQR-
SEQ20F, RNA SQR-SEQRNA, DNA SQR-SEQDNA, and 20F SQR-
SEQDNA) were studied for comparison. It was found that 20F
SQR-SEQ20F remained most stable compared with the other coun-
terparts (Figure 2A). DNA SQR-SEQDNA began to degrade within
10 min and was completely degraded by 12 hr. Substitution of the
20F SQR core structure in place of the DNA SQR resulted in a
remarkable improvement on nuclease resistance. A distinguishable
increase in the migration rate of gel bands between 1 and 12 hr
time points of 20F SQR-SEQDNA suggests that the four external
SEQDNA strands, which were hybridized to 20F SQR, were degraded,
whereas the 20F SQR core structure remained stable. After 24 hr,
54.6% of 20F SQR-SEQ20F remained intact, compared with 3.5%
for RNA SQR-SEQRNA, 2.3% for DNA SQR-SEQDNA, and 44.2%
for 20F SQR-SEQDNA. Furthermore, the melting temperature (Tm)
of 20F SQR-SEQ20F, RNA SQR-SEQRNA, and DNA SQR-SEQDNA
nanoparticles was determined to be 75.0C, 57.5C, and 48.3C,
respectively, by a perpendicular temperature gradient gel electro-
phoresis (TGGE) (Figure 2B). The serum degradation assay and
Tm measurement indicate that the 20F SQR-SEQ20F nanoparticle ex-
hibited the highest chemical and thermodynamic stability compared
with other compositions.
Binding of 20F SQR with Extended Special SEQ to Macrophage-
like RAW 264.7 Cells
The effective delivery to targeted cells is important to elicit immu-
nomodulatory activity. Unfortunately, many small nucleic acid
therapeutics, such as short single-stranded antisense oligos, have
shown difficulty in binding to or entering cells because of their
negative charge and small size, and were either expelled by the
negatively charged cell membrane or were excluded from macro-
phage engulfment.66,67 To demonstrate increased cellular binding
of RNA nanoparticles compared with small ssRNA, we incubated
both Cy3-labeled 20F SQR-SEQ (50 nM) and 20F SEQ (200 nM)
with macrophage-like RAW 264.7 cells at equimolar concentration
of SEQ and evaluated them by confocal microscopy. Co-localiza-
tion of the Cy3 signal (red) and cellular actin (green) in confocal
Figure 2. Serum Stability Assay and Tm Measurement of Different SQR-SEQ Nanoparticles
(A) Serum stability of (a) 20F SQR-SEQ20F, (b) RNA SQR-SEQRNA, (c) DNA SQR-SEQDNA, and (d) 20F SQR-SEQDNA assayed in 10% FBS supplemented cell culture medium.
(B) Tm measurement of 2
0F SQR-SEQ20F, RNA SQR-SEQRNA, and DNA SQR-SEQDNA by temperature gradient gel electrophoresis (TGGE). Quantification analysis of intact
nanoparticles % was performed by ImageJ.
www.moleculartherapy.org
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imaging indicates that 20F SQR-SEQ strongly bind to RAW 264.7
cells, whereas only weak Cy3 signal was observed in the 20F SEQ
group (Figure 3). This suggests that macrophage binding occurred
in a size-dependent manner because larger RNA nanoparticles can
be caught by the RAW 264.7 cells much easier than smaller ones. In
addition, flow cytometry analysis showed that the cellular binding
events rose with increasing copies of 20F SEQ per nanoparticle
(Figure S2).
Comparison of the Immunostimulation of RNA Nanoparticles
with Different Sizes and Stoichiometries
It has been reported that physicochemical properties of particles will
affect their interaction with the body’s immune system, triggering
different levels of immune responses.63,65,68–71 In this study, 20F small
(7.10 nm), medium (12.31 nm), and large (21.15 nm) SQRs with SEQ
extensions were constructed at the same concentration (50 nM) for
the study of size-dependent immunomodulation. The immunostimu-
latory activity was evaluated by using ELISA to measure the stimu-
lated cytokine levels of tumor necrosis factor-a (TNF-a) and
interleukin-6 (IL-6). The small 20F SQR-SEQ nanoparticle elevated
the immunomodulation to some extent, while a more significant
improvement was observed with medium and large 20F SQR-SEQ
nanoparticles (Figure 4A). These results indicate that RNA nanopar-
ticles display immunoactivity in a size-dependent manner, and their
size should be greater than 7 nm to exhibit significant immunomodu-
lation. We also evaluated medium 20F SQRs harboring different
numbers of 20F SEQ modules and observed that the responses
increased in a stoichiometry-dependent manner. It can be found
that incorporating more 20F SEQ to 20F SQR (50 nM) led to higher
cytokine secretion levels (Figure 4B).
Comparison of the Immunostimulation of RNA Nanoparticles
with Different Shapes
20F RNA triangle, square, and pentagon with the extension of SEQ
were designed to be close in size and constructed by stretching the in-
Figure 3. Cellular Binding Comparison of Medium
2’F SQR-SEQ and 2’F SEQ
Confocal images showing the cellular binding comparison
of medium 20F SQR-SEQ and 20F SEQ to macrophage-
like RAW 264.7 cells by co-localization of nucleus (blue),
cytoplasm (green), and Cy3-labeled nanoparticles (red)
signals.
ner AOB angle to 60, 90, or 108.59 It was
observed that higher cytokine secretion levels
were induced with the transition from triangle,
to square, and to pentagon at the same concen-
tration (50 nM) (Figure 5A). This should be
due to the different stoichiometry of the RNA
polygons with different shapes (pentagon,
square, and triangle can carry five, four, and
three SEQ modules, respectively). As negative
controls, nude 20F RNA triangles without
extended SEQ were assessed, but no obvious cytokine secretion was
observed.
To compare the effect of planar and three-dimensional RNA nano-
structures on enhancing immunomodulation, we constructed a well-
characterized 20F RNA Th43 with three extended SEQ (Dh = 11.18 ±
2.28 nm) (Figures S1 and S3). 20F Th-SEQ was used to compare
with 20F TRI-SEQ because both harbor three SEQ extensions. It
was observed that the 20F Th-SEQ (50 nM) elicited a much stronger
immune response than the 20F TRI-SEQ (50 nM) (Figure 5B). Tak-
ing the free 20F SEQ control (150 nM) into consideration, it suggests
a possible rule that the immunogenicity of RNA nanoparticles will
increase with the transition from linear, to planar, and to three-
dimensional structures. Our results demonstrate that the size and
shape of RNA nanoparticles have an essential effect on the immune
response elicited by the extended 20F SEQ. It is suggested that it
would be beneficial to control the immunoactivity of RNA nanopar-
ticles through altering size or shape to reach a desired level.
Special RNA SEQs as Key Factors in the Immunogenicity of RNA
Nanoparticles as Revealed in Cell Assay and Animal Trial
Some specific RNA SEQs were reported to trigger immune response
because of their recognition and specific interaction with various
TLRs (TLR-3, -7, and -8) or cytosolic sensors (PKR, RIG-1, and
MDA-5) that are widely expressed on immune cells.15–18,29–33 To
study the importance of SEQ specificity in immunomodulation of
RNA nanoparticles, we employed four ssRNA SEQs (20F SEQ,
Mut I, Mut II, and a scramble SEQ control; see Table S1) as external
extensions to the medium SQR for comparison. The free 20F SEQ
(200 nM) only induced low response (Figure 6A). However, exten-
sions of SEQ from the vertexes of 20F SQR (50 nM) resulted in strong
immunostimulations of cytokines TNF-a and IL-6 (Figures 4 and 6).
The results suggest that the specific RNA SEQs extensions play a cen-
tral role, because the 20F SQR-SEQ enhanced immune response, while
the effects of 20F SQR-Mut SEQ I (50 nM) and 20F SQR-Mut SEQ II
Molecular Therapy: Nucleic Acids
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(50 nM) were reduced and almost abolished, respectively. Negligible
immune response was detected for 20F SQR with extended random
SEQ (20F SQR-scramble, 50 nM), our negative control. In addition,
blocking of 20F SEQ at the end of the vertexes by a complementary
ssRNA strand resulted in decreased cytokine stimulation (Figure S4).
More importantly, we have demonstrated the ability to tune their im-
munoactivity by simply varying the extended SEQ. To further confirm
immunomodulation, we analyzed the activation of the cytokine
signaling pathway in RAW 264.7 cells stimulated by the medium 20F
SQR-SEQby immunoblotting assay. The significantly enhanced phos-
phorylation of IkB-a protein could subsequently activate NF-kB and
inflammatory responses, and demonstrates that 20F SQR-SEQ ex-
hibited strong immunostimulatory activity (Figure 6Ba). ICAM-1
(Intercellular Adhesion Molecule 1), another protein marker involved
in the pro-inflammatory pathways,was alsoupregulated in the 20F SQR-
SEQ-treated group (Figure 6Bb). As a control, the unmodified RNA
SQR-SEQ only triggered low or negligible effects because of their insta-
bility in serum environment. Next, 20F SQR-SEQ was systemically in-
jected into CD-1 mice to evaluate the immunostimulation in vivo. After
3 hr post-injection, 20FSQR-SEQ induced significant cytokine induction
in mice, whereas the nude 20F SQR control showed undetectable effect
(Figure 6C). This result is consistent with the in vitro results, confirming
that RNA nanoparticles are immune inert in vivo but can be manipu-
lated to be immune active with the extensions of special RNA SEQs.
DISCUSSION
Drug safety profiles including toxicity, side effects, and immunoge-
nicity are essential for drug evaluation. Nanotechnology-based
carriers have been widely used for the delivery of therapeutics because
there are numerous advantages to using nanoparticles over traditional
routes.41,72–74 However, certain detrimental immune responses have
also been reported, leading to some concerns.63–65 It has been pointed
out that these side effects might be caused by a wide range of
physicochemical properties such as surface charge, solubility, or hy-
drophobicity.63–65 Thus, controlling the immune response triggered
by nanoparticles remains one of the challenges for many nano-deliv-
ery systems. Notably, the physicochemical properties of RNA
nanoparticles are tunable, making them an attractive nanomaterial.
Their size, shape, sequence, stoichiometry, and other properties
can be controlled at ease, and the procedures and process for
RNA nanoparticles construction is reproducible. Therefore, their
immunomodulatory effect can be controlled precisely through
rational design.
It has been previously shown that RNA nanoparticles themselves
might not display intrinsic immunogenicity.59,60 That premise is sup-
ported here by this work. Incorporation of a special SEQ to RNA
nanoparticles endows them with strong immunostimulatory activity
compared with RNA nanoparticles without extension controls (Fig-
ures 4, 5, and 6). It was found that size is one of the important deter-
minants of immunostimulation. Previous studies reported that nano-
particles ranging from 10 to 100 nm are favorable for effective
delivery to target tissues or cells, because they are large enough to
avoid rapid renal excretion, but small enough for cell entry via recep-
tor-mediated endocytosis.75–77 Larger particles will be recognized by
the reticuloendothelial system (RES) more easily and prolong reten-
tion within the liver. In contrast, small nanoparticles less than
10 nm are rapidly eliminated from the body via renal filtration,
though they can escape from trapping by the RES. In addition,
the complement system is another key part of the immune system.
It recognizes abnormal detrimental signals rapidly, coating intruders
with opsonins and eliminating them by complement receptors
bearing phagocytes. It was reported that some physicochemical pa-
rameters, especially surface charge and surface-projected polymers,
affect complement sensing.78 For example, some cationic polymers
such as polyethyleneimines are confirmed to activate complement
pathways,79 whereas an anionic vesicle modified with carboxylic
acid failed to induce activation.80 Thus, RNA nanoparticles benefit
from their polyanionic nature that minimizes the non-specific inter-
action with negatively charged cell membranes. Moreover, the
nanoparticle size also plays a role. It was reported that the bulky op-
sonins such as C3b molecules prefer to assemble and deposit onto
Figure 4. Size- and Stoichiometry-Dependent Cytokines Induction in RAW 264.7 Cells by 20F SQR-SEQ
(A) Cytokines (a) TNF-a and (b) IL-6 induction by small (S), medium (M), and large (L) 20F SQR-SEQ. (B) Cytokine TNF-a induction by medium 20F SQR-SEQ with different
numbers of extensions (concentrations refer to nanoparticles; fold changes were determined by normalizing the cytokine level elicited by 20F SQR without extension as 1;
results are presented as mean ± SD; n = 3; *p < 0.05; **p < 0.01; ***p < 0.001, analyzed by Student’s t test).
www.moleculartherapy.org
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the surface of larger nanoparticles or microparticles.81 For nanopar-
ticles that are smaller than 30 nm, the opsonins tend to be released
into the surrounding medium because of the limited
accommodation, suggesting that a small RNA nanoparticle
(10–20 nm) may be a poor activator of the complement system.
In this study, the RNA polygons were designed to be smaller than
30 nm. RNA polygons with SEQ extensions in larger size
(10–20 nm) significantly enhanced immunomodulation effects,
compared with the small one (7.1 nm) (Figure 4A). As demon-
strated by confocal microscopy imaging, the larger the RNA nano-
particle size, the more efficient it is in cell binding to RAW 264.7
cells (Figure 3). The mechanism might be attributed to the engulfing
property of macrophages. Additionally, the levels of immunomodu-
lation varied depending on RNA nanoparticle shapes (Figure 5). It
is worth noting that the 3D 20F Th-SEQ displayed a stronger cyto-
kine induction compared with the planar 20F TRI-SEQ, when both
were similar in size and loaded with three 20F SEQ modules (Fig-
ure 5B), demonstrating another dimension of immune response
control. More importantly, cytokine induction by different SEQ
extensions reveals that SEQ plays a dominant role in the immuno-
genicity of RNA nanoparticles, and only specific RNA SEQ
would induce strong immunostimulation (Figure 6A). The SEQ
Figure 5. Shape-Dependent Cytokines Induction in
RAW 264.7 Cells by 20F RNA Nanoparticles
(A) Cytokines (a) TNF-a and (b) IL-6 induction by 20F TRI-
SEQ, 20F SQR-SEQ, and 20F PENTA-SEQ. (B) Cytokines
(a) TNF-a and (b) IL-6 induction by planar 20F TRI-SEQ
and 3D 20F Th-SEQ (concentrations refer to nano-
particles; fold changes were determined by normalizing
the cytokine level elicited by 20F TRI without extension
as 1; results are presented as mean ± SD; n = 3; *p <
0.05; **p < 0.01; ***p < 0.001, analyzed by Student’s
t test).
that caused the strongest immune response is
the one that holds strong homology to CpG-
1826 oligodeoxynucleotide (ODN; 20-mer), a
well-studied immunological adjuvant discov-
ered from bacterial DNA that binds to the
TLR-9.82
RNA nanotechnology is an emerging field, but
the study of its immunogenicity is still at an
early stage. More investigations on this aspect
are of great significance for progressing to-
ward clinical studies. Our studies have pro-
vided important implications for exploring
the mechanism behind the immunogenicity
of RNA nanoparticles. By tuning their proper-
ties, certain resulting RNA nanoparticles can
be employed as safe therapeutic carriers
without triggering immune response,46–49,58
or as potential immunomodulators for immu-
notherapy. Also, it should be noted that this study was performed
in a murine macrophage model that might not fully represent the
situations of human cells. There is a distinct difference between
human cells and mouse cells regarding TLR-9 response. In
humans, only B cells and plasmacytoid dendritic cells express
TLR-9. In mice, however, most other dendritic cells and macro-
phages express TLR-9. Therefore, more studies are required in
the future to perform on human cell models to explore a more
comprehensive mechanism related to clinical applications.
MATERIALS AND METHODS
RNA Nanoparticle Design, Synthesis, and Self-Assembly
The 3D computational model of RNA nanoparticle was generated
in Swiss PDB Viewer and PyMOL Molecular Graphics System, us-
ing a pRNA-3WJ crystal structure (PDB: 4KZ2), as previously
described.83 In brief, the ultra-stable pRNA-3WJ motif was placed
at each vertex of the RNA core polygon structure, stretching the
inner AOB angle to accommodate polygon geometry (Fig-
ure 1A).54,59 ssRNAs were synthesized by in vitro T7 transcription,
as previously described.84 For synthesizing 20F-modified RNA,
the Y693F mutant T7 polymerase and 20F pyrimidine trinucle-
otides were used.85 DNA templates were produced by PCRs
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using DNA oligomers ordered from IDT (Integrated DNA Tech-
nologies). RNA transcripts were then purified using 8 M urea,
8% denaturing PAGE. All RNA nanoparticles were self-assembled
in a one-pot manner by mixing individual RNA strands at equi-
molar concentrations (10 mM) in 1 TMS buffer (50 mM Tris
[pH 8.0], 100 mM NaCl, and 10 mM MgCl2) and heated to
95C, followed by slowly cooling down to 4C. Stepwise self-assem-
bly was verified by 3% agarose gel electrophoresis with ethidium
bromide (EB) staining and imaged by Typhoon FLA 7000 (GE
Healthcare).
DLS
RNA nanoparticles harboring SEQ extensions were preassembled at
0.5 mM in 50 mL 1 TMS buffer. The apparent hydrodynamic size
of assembled RNA nanoparticle was measured by Zeta-sizer nano-ZS
(Malvern Instruments) at 25C with at least three independent mea-
surements. The laser wavelength was 633 nm.
Serum Degradation Assay and TGGE Assay
Preassembled nanoparticles were incubated at the final concen-
tration of 1 mM in cell culture medium that contained 10% fetal
bovine serum (FBS) at 37C for various time points and then
were examined by 3% agarose gel at 90 V for 40 min. After being
stained with EB and imaged by Typhoon FLA 7000, quantification
analysis was performed using ImageJ software to calculate the
Figure 6. Sequence-Dependent Cytokines
Induction and Immune Markers Activation in RAW
264.7 Cells and Mice by 20F SQR-SEQ
(A) Cytokines (a) TNF-a and (b) IL-6 induction by medium
20F SQR with SEQ, mutated SEQ, and scramble RNA
(concentrations refer to nanoparticles; fold changes were
determined by normalizing the cytokine level elicited by
20F SQR-Scramble as 1). (B) Activation of (a) phosphor-
ylated-IkB-a (Ser32) and (b) ICAM-1 (CD54) stimulated by
medium 20F SQR-SEQ. (C) Cytokines TNF-a and IL-6
induction by medium 20F SQR-SEQ in mice (concentra-
tions refer to SEQ per body weight; results are presented
as mean ± SD; n = 3; *p < 0.05; **p < 0.01; ***p < 0.001,
analyzed by Student’s t test).
percentage of intact nanoparticles over time.
Quantified values of gel bands for each nano-
particle were divided by the value of
first nanoparticles at 0 min and then plotted
by OriginLab software.
TGGE analysis was performed on 6% native
PAGE in 1 TBE buffer (89 mM Tris-borate
[pH 8.0] and 2mMEDTA) as reported before.86
In brief, a gradient temperature from 30C to
80C was applied perpendicular to electrical
current in PAGE and run for 60 min at 20 W.
Quantified values of bands for each nanopar-
ticle were divided by the sum of the total values
in corresponding lanes. Tm values were defined as the temperature at
which 50% of loaded nanoparticle was dissociated.
Cell Culture
Murine macrophage-like RAW 264.7 cells were grown at 37C in hu-
midified air environment containing 5% CO2, cultured in DMEM
containing both 10% (v/v) FBS and 100 U/mL penicillin.
Confocal Microscopy Imaging
RAW 264.7 cells were seeded on glass coverslips and cultured at 37C
overnight. RNA nanoparticles were labeled with Cy3 fluorophore at
the 50 end of one of the ssRNAs. 200 nM 20F SEQ and 50 nM 20F
SQR-SEQ were incubated with cells for 4 hr at 37C. After washing
twice with 1 PBS, cells were fixed with 4% formaldehyde, followed
by staining with ProLong Gold Antifade Reagent with DAPI (Life
Technologies Corporation, Carlsbad, CA, USA) for cell nucleus and
Alexa Fluor 488 phalloidin (Life Technologies Corporation) for cyto-
skeleton. Confocal images were taken by Olympus FV1000 confocal
microscope (Olympus Corporation, Tokyo, Japan).
Evaluation of Cytokines Induction by ELISA
2.5  105/well RAW 264.7 cells were seeded in 24-well plates and
cultured overnight. RNA nanoparticles were diluted in Opti-MEM
medium (Life Technologies Corporation) to final concentration of
50 nM and incubated with cells at 37C for 8 hr. Next, cell culture
www.moleculartherapy.org
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supernatants were collected and stored at80C until assay. Concen-
trations of TNF-a and IL-6 in collected supernatants were examined
by using Mouse ELISA MAX Deluxe sets (BioLegend, San Diego,
CA, USA), following the protocol provided by the manufacturer.
Experiment results were repeated for at least three independent
measurements. Data were statistically analyzed by Student’s t test
and were presented as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001.
Immunoblotting Assay
4  105/well RAW 264.7 cells were seeded in 24-well plates and
cultured overnight, followed by treatment with RNA nanoparticles
(50 nM) at 37C for 8 hr. Cells were treated with cell lysis buffer con-
taining protease inhibitor and phosphatase inhibitor (Cell Signaling
Technology, Beverly, MA, USA) for protein extraction. Total proteins
were separated by 7.5% SDS-PAGE and transferred to polyvinylidene
difluoride membranes (Bio-Rad, Hercules, CA, USA). The mem-
branes were blocked in 5% milk for 2 hr at room temperature and
incubated overnight with antibodies (Abs) at 4C. Immunoblots
were developed using a chemiluminescent substrate and exposed to
imaging films. The same membrane was re-probed with anti-actin
(1:4,000) as an internal control. Antibodies used were ICAM-1 (M-
19) (sc-1511) and rabbit anti-goat IgG-horseradish peroxidase
(HRP) (sc-2768) from Santa Cruz (Santa Cruz, CA, USA); phos-
pho-IkB-a (Ser32) (14D4) rabbit monoclonal antibody (mAb), IkB-
a (L35A5)mousemAb (amino-terminal antigen), b-actin (13E5) rab-
bit mAb (HRP conjugate), anti-rabbit IgG HRP-linked Ab, and anti-
mouse IgG HRP-linked Ab from Cell Signaling Technology.
In Vivo Immunostimulation in Mice
All animal procedures were housed and performed in accordance
with the Subcommittee on Research Animal Care of The Ohio State
University guidelines approved by the institutional review board.
Male CD-1 mice (4–5 weeks old) were purchased from Charles River
Laboratories. RNA nanoparticles were injected into mice via tail vein
injection at 2 mg/kg (SEQ per body weight). After 3 hr post-injection,
blood samples were harvested from mice by cardiac puncture and
centrifugated at 12,800  g for 10 min. Concentrations of TNF-a
and IL-6 in serum supernatant were examined by ELISA as described
above.
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SUPPLEMENTAL INFORMATION: 
 
Supplemental Figures:  
Figure. S1. Step-wise self-assembly of small, medium and large 2’F SQR-SEQ, 2’F TRI-SEQ, 2’F 
PENTA-SEQ and 2’F Tetrahedron-SEQ evaluated by 3% agarose gel (M=monomer, D=dimer, 
T=trimer, Tetra=tetramer, P=pentamer; ladder: 100 bp DNA). 
 
Figure. S2. Flow cytometry analysis showing the increased cellular binding of medium 2’F SQR-SEQ 
to RAW 264.7 cells as more copies of 2’F SEQ incorporated (2’F SQR-2 SEQ refers to 2’F Square with 
two SEQ extensions on the neighboring vertexes, and 2’F SQR-2’ SEQ means 2’F Square with two SEQ 
extensions on the opposite vertexes). 
M
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T
  
Figure. S3. Size distribution histogram of 2’F Tetrahedron (Th)-SEQ measured by DLS (n=3). 
 
 
 
 
 
Comparison of 2’F SQR-SEQ and 2’F SQR-double-stranded SEQ 
  a. Cytokine TNF-α induction              b. Cytokine IL-6 induction 
Figure. S4. Cytokines a. TNF-α and b. IL-6 induction by medium 2’F SQR-SEQ, 2’F 
SQR-double-stranded SEQ and control groups (concentrations refer to nanoparticles; results were 
presented as mean±standard deviation, n=3, **P<0.01, ***P<0.001, analyzed by student’s t test). 
  
 
 
Table S1. Sequences for primary RNA nanoparticles (5’→3’) 
SEQ (20nt) UCCAUGACGUUCCUGACGUU 
Mutated SEQ I (20nt) UCCAUGAGCUUCCUGACGUU 
Mutated SEQ II (20nt) UCCAUGAGCUUCCUGAGCUU 
Scramble sequence(20nt) GCAGCUUUGGCUGAGCGUAU 
Complementary SEQ (20nt) AACGUCAGGA ACGUCAUGGA 
Small SQR A-SEQ (63nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGACCGU
ACUUUGUUGCACGCCC 
Small SQR B-SEQ (63nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGCGACCCAAUCAUGUCUCU
ACUUUGUUGGCUGGCC 
Small SQR C-SEQ (63nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGCCAGCCAAUCAUGCACAU
ACUUUGUUGACGGCCC 
Small SQR D-SEQ (63nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGUAGUU
ACUUUGUUGGGUCGCC 
Small SQR E (48nt) GGUCAUGUGUAUGUGCAUGUGUAGAGACAUGUGUAACUACAUGUGU
AC 
Medium SQR A-SEQ (73nt) 
TRI A-SEQ (73nt) 
PENTA A-SEQ (73nt) 
GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGGCAAG
UGUCCGCCAUACUUUGUUGCACGCCC 
Medium SQR B-SEQ (73nt) 
PENTA B-SEQ (73nt) 
GGUCCAUGACGUUCCUGACGUUUUUUUGGCGACCCAAUCAUGGCAAC
GAUAGAGCAUACUUUGUUGGCUGGCC 
Medium SQR C-SEQ (73nt) 
TRI C-SEQ (73nt) 
PENTA C-SEQ (73nt) 
GGUCCAUGACGUUCCUGACGUUUUUUUGGCCAGCCAAUCAUGGCAAU
AUACACGCAUACUUUGUUGACGGCCC 
Medium SQR D-SEQ (73nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGACAAG
CGCAUCGCAUACUUUGUUGGGUCGCC 
Medium SQR E (88nt) GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA
UCGUUGUCAUGUGUAUGCGAUGCGCUUGUCAUGUGUAUGGC 
TRI B-SEQ (73nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGGCAAC
GAUAGAGCAUACUUUGUUGGCUGGCC 
TRI D (66nt) GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA
UCGUUGUCAUGUGUAUGGC 
PENTA D-SEQ (73nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGCCCUACAAUCAUGGCAAG
CGCAUCGCAUACUUUGUUGGGUCGCC 
PENTA E-SEQ (73nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGGCAAA
UAUGCGCCAUACUUUGUUGUAGGGCC 
PENTA F (110nt) GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA
UCGUUGUCAUGUGUAUGCGAUGCGCUUGUCAUGUGUAUGGCGCAUAU
UUGUCAUGUGUAUGGC 
Large SQR A-SEQ (93nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGGCAAG
UGUCCGCAAGCAUAGCUCGGAUAGCCUCAUACUUUGUUGCACGCCC 
Large SQR B-SEQ (93nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGCGACCCAAUCAUGGCAAC
GAUAGAGGCAUAGUCGACCUAUGCAUCCAUACUUUGUUGGCUGGCC 
Large SQR C-SEQ (93nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGCCAGCCAAUCAUGGCAAU
AUACACGCGAGUUGCCACGAGGACGCUCAUACUUUGUUGACGGCCC 
Large SQR D-SEQ (93nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGACAAG
CAUCGCAUUCCGUGUCGUAGUCCUUCGCAUACUUUGUUGGGUCGCC 
Large SQR E (168nt) GGACACUUGUCAUGUGUAUGAGCGUCCUCGUGGCAACUCGCGUGUAU
AUUGUCAUGUGUAUGGAUGCAUAGGUCGACUAUGCCUCUAUCGUUGU
CAUGUGUAUGCGAAGGACUACGACACGGAAUGCGAUGCUUGUCAUGU
GUAUGAGGCUAUCCGAGCUAUGCUUGC 
Th A-SEQ (115nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGACUGAUACGAAUCAUCGU
GUAGCACCAGCUGUAAUCGAUGUGUACGGGAAGAGCCUAUGCCCAUC
CUACUUUGUUCUACUAUGGCG 
Th B-SEQ (115nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGUGCUACACGAUGUGUAGC
CAGACUUAGCGGAAUGUUCGUACUUUGUUCAUGCGAGGCCGUCCAAU
ACCGAAUCAUCGAUUACAGCU 
Th C-SEQ (115nt) GGUCCAUGACGUUCCUGACGUUUUUUUGGGCAGUUGAGAUGUGUACG
AACAUUCCGCUAAGUCUGGCUACUUUGUUCGUAUCAGUCCCGCCAUA
GUAGAAUCAUCGUAUCACCAU 
Th D (88nt) GGCCUCGCAUGAAUCAUCUCAACUGCCCAUGGUGAUACGAUGUGUAG
GAUGGGCAUAGGCUCUUCCCGUACUUUGUUCGGUAUUGGAC 
RNA SQR  
(small, medium & large) 
Reference (54) 
RNA TRI, SQR & PENTA Reference (59) 
RNA Th Reference (43) 
(SEQ: specific sequence, TRI: triangle, SQR: square, PENTA: pentagon, Th: tetrahedron) 
 
 
 
Supplemental Methods: 
 
Flow Cytometry Assay 
5 × 105 RAW 264.7 cells were suspended in Opti-MEM medium in 1.5mL eppendorf tubes. Cy3-labled 
RNA nanoparticles were diluted in Opti-MEM medium at 100nM and incubated with cells at 37 °C for 
1.5 hours. After washing with PBS buffer (137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4) to remove unbound nanoparticles, cells were re-suspended in PBS buffer and the cell 
binding efficacy was determined by FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). 
